On slicing an obvious salami thinly: science, patent case law, and the fate of the early biotech sector in the making of EPO.

Abstract

This essay reconstructs in previously unavailable detail the 1980s race to clone and market what would be biotechnology's most important product to date, erythropoietin or EPO. The scientific contest continued into the U.S. courts, which were charged with deciding competing patent claims to the natural substance as a drug. Through case law in the new domain… (More)
DOI: 10.1353/pbm.2013.0016

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.